Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

María Carcelén-Gadea

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Transfusion|February 1, 2019
The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosisCarlos Quintanilla-Bordás, Emma Castro-Izaguirre, María Carcelén-Gadea, et al.
Frontiers in Neurology|November 22, 2021
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-SpainLamberto Landete, Francisco Pérez-Miralles, Sara García, et al.
European Neurology|January 5, 2017
Observational Study of Switching from Natalizumab to Immunomodulatory DrugsRamón Villaverde-González, Julia Gracia Gil, Angel Pérez Sempere, et al.
Multiple Sclerosis and Related Disorders|March 18, 2020
Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple SclerosisJorge Maurino, María L Martínez-Ginés, José M García-Domínguez, et al.
European Neurology|July 5, 2016
Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical PracticeJosé Meca-Lallana, Luis Hernández, Ana Belén Caminero, et al.
Brain and Behavior|November 17, 2019
Functional and structural changes in the visual pathway in multiple sclerosisMaría Carcelén-Gadea, Carlos Quintanilla-Bordás, Alicia Gracia-García, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 12, 2017
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosisBonaventura Casanova, Isidro Jarque, Francisco Gascón, et al.
Journal of Neurology|February 2, 2022
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational studyCarmen Alcalá, Carlos Quintanilla-Bordás, Francisco Gascón, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 9, 2018
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patientsBonaventura Casanova, Laura Lacruz, María Luisa Villar, et al.
Frontiers in Neurology|November 17, 2022
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosisCarmen Alcalá Vicente, Laura Lacruz, Francisco Gascón, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Transfusion|February 1, 2019
The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosisCarlos Quintanilla-Bordás, Emma Castro-Izaguirre, María Carcelén-Gadea, et al.
Frontiers in Neurology|November 22, 2021
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-SpainLamberto Landete, Francisco Pérez-Miralles, Sara García, et al.
European Neurology|January 5, 2017
Observational Study of Switching from Natalizumab to Immunomodulatory DrugsRamón Villaverde-González, Julia Gracia Gil, Angel Pérez Sempere, et al.
Multiple Sclerosis and Related Disorders|March 18, 2020
Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple SclerosisJorge Maurino, María L Martínez-Ginés, José M García-Domínguez, et al.
European Neurology|July 5, 2016
Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical PracticeJosé Meca-Lallana, Luis Hernández, Ana Belén Caminero, et al.
Brain and Behavior|November 17, 2019
Functional and structural changes in the visual pathway in multiple sclerosisMaría Carcelén-Gadea, Carlos Quintanilla-Bordás, Alicia Gracia-García, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 12, 2017
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosisBonaventura Casanova, Isidro Jarque, Francisco Gascón, et al.
Journal of Neurology|February 2, 2022
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational studyCarmen Alcalá, Carlos Quintanilla-Bordás, Francisco Gascón, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 9, 2018
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patientsBonaventura Casanova, Laura Lacruz, María Luisa Villar, et al.
Frontiers in Neurology|November 17, 2022
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosisCarmen Alcalá Vicente, Laura Lacruz, Francisco Gascón, et al.
Pageof 2